Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.02 is 133% above its 2-year average of -0.07, near the high end of its 2-year range (-0.16–0.02).
As of the fiscal period ended Tuesday, June 30, 2026. 175.65% above its 12-month average of -0.03.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.02.
DEBT TO EQUITY RATIO
0.02
DEBT TO EQUITY RATIO AVG TTM
-0.03
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+175.65%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 516 covered companies
CURRENT VS SECTOR MEDIAN
-82.83%
vs the sector median at left
Aktis Oncology, Inc.
Market Cap
$978.64M
Debt to Equity Ratio
0.02
TTM Avg
-0.03
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$967.55M
Debt to Equity Ratio
0.02
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$983.05M
Debt to Equity Ratio
0.52
TTM Avg
0.95
3Y Avg
0.70
5Y Avg
0.50
Market Cap
$1.00B
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$997.34M
Debt to Equity Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$997.11M
Debt to Equity Ratio
0.02
TTM Avg
0.02
3Y Avg
0.05
5Y Avg
0.03
Market Cap
$1.01B
Debt to Equity Ratio
1.94
TTM Avg
1.61
3Y Avg
1.30
5Y Avg
1.21
Market Cap
$1.01B
Debt to Equity Ratio
1.59
TTM Avg
4.87
3Y Avg
5.44
5Y Avg
5.44
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aktis Oncology, Inc. (AKTS) | $978.64M | 0.02 | -0.03 | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $967.55M | 0.02 | 0.01 | 0.01 | 0.01 |
| MeiraGTx Holdings plc (MGTX)vs › | $983.05M | 0.52 | 0.95 | 0.70 | 0.50 |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.00B | 0.01 | 0.01 | 0.01 | 0.01 |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $997.34M | N/A | N/A | N/A | N/A |
| Janux Therapeutics, Inc. (JANX)vs › | $997.11M | 0.02 | 0.02 | 0.05 | 0.03 |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.01B | 1.94 | 1.61 | 1.30 | 1.21 |
| Immatics N.V. (IMTX)vs › | $1.01B | 0.04 | 0.03 | 0.05 | 0.11 |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.01B | 1.59 | 4.87 | 5.44 | 5.44 |
| CeriBell, Inc. (CBLL)vs › | $927.32M | 0.17 | 0.13 | 0.13 | 0.13 |
Debt/Equity
0.02
Current Ratio
16.33
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.02 |
| 2026-03-31 | 0.02 |
| 2025-12-31 | -0.08 |
| 2025-09-30 | -0.09 |
| 2024-12-31 | -0.14 |
| 2024-09-30 | -0.16 |
